C4 Therapeutics shares surge 12.55% after-hours as TD Cowen initiates Buy rating amid positive analyst trend.

C4 Therapeutics surged 12.55% in after-hours trading following TD Cowen’s initiation of coverage with a Buy rating. The move aligns with a broader trend of positive analyst sentiment, as multiple firms including Barclays, Wells Fargo, and Stephens & Co. have recently upgraded or raised price targets for the biotechnology company. TD Cowen’s entry into coverage, coupled with prior upgrades and elevated price targets from peers, underscores growing confidence in C4 Therapeutics’ pipeline and its TORPEDO platform for targeted protein degradation. The stock’s sharp post-market rise reflects investor optimism over the company’s potential to advance its oncology programs and address undruggable targets, supported by a consensus of "Outperform" ratings from seven brokerage firms.